NCT02873975: A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

NCT02873975
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: ATM, BRCA+, CCNE1, DNA damage repair mutations, MYC
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients must have one of the following mutations: ATM, MYC (amplification), Cyclin E or CCNE1 (amplification), or a DNA repair deficiency including ATR, BRCA1/2, PALB2, CHEK2, FANC, or RAD51C/D mutations
Exclusions: Patients with known untreated unstable brain metastases; Patients who have received prior treatment with a CHK1 inhibitor
https://ClinicalTrials.gov/show/NCT02873975

Comments are closed.

Up ↑